|
Hemato-oncology
The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
Gi-June Min, Young-Woo Jeon, Sung-Soo Park, Silvia Park, Seung-Hawn Shin, Seung-Ah Yahng, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Dong-Wook Kim, Jong-Wook Lee, Seok-Goo Cho
Korean J Intern Med. 2021;36(2):424-432. Published online February 24, 2020
Background/Aims: Idiopathic multicentric Castleman disease (iMCD) comprises approximately 30% of all cases of Castleman disease. It is characterized by constitutional symptoms, enlarged lymph nodes at multiple anatomical sites, and laboratory test abnormalities, which are primarily related to the o..
|
|
|
Cardiology
Association between left ventricular function and paraprotein type in patients with multiple
myeloma
Jeong-Eun Yi, Sung-Eun Lee, Hae-Ok Jung, Chang-Ki Min, Ho-Joong Youn
Korean J Intern Med. 2017;32(3):459-468. Published online April 6, 2016
Background/Aims: Multiple myeloma (MM)–associated cardiac damage, particularly according to the type of monoclonal (M) protein has not been elucidated. We sought to investigate relationship between elevated serum M protein levels and echocardiographic indices of cardiac structure and function in pa..
|
|
|
Hemato-oncology
Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: a Korean single-center, retrospective clinical study
Young-Woo Jeon, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Chang-Ki Min, Jong Wook Lee, Woo-Sung Min, Seok-Goo Cho
Korean J Intern Med. 2015;31(5):944-952. Published online July 7, 2016
Background/Aims: Recently, large cohort studies regarding associations between autoimmune disease and lymphomas have been reported in a few Western countries. However, Asian data concerning autoimmune-related lymphomas are limited. Therefore, we evaluated the clinical characteristics and prognostic ..
|
|
|
Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
Ho Sup Lee, Chang-Ki Min
Korean J Intern Med. 2016;31(5):809-819. Published online September 1, 2016
Multiple myeloma is an incurable malignant plasma cell-originating cancer. Although its treatment outcomes have improved with the use of glucocorticoids, alkylating drugs, and novel agents, including proteasome inhibitors (bortezomib and carfilzomib) and immunomodulatory drugs (thalidomide, lenalido..
|
|
|
The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
Cheolsu Kim, Ho Sup Lee, Chang-Ki Min, Je Jung Lee, Kihyun Kim, Dok Hyun Yoon, Hyeon Seok Eom, Hyewon Lee, Won Sik Lee, Ho-Jin Shin, Ji Hyun Lee, Yong Park, Jae-Cheol Jo, Young Rok Do, Yeung-Chul Mun
Korean J Intern Med. 2015;30(5):675-683. Published online August 27, 2015
Background/Aims: The purpose of this study was to determine the correlations between inflammatory factors—including absolute lymphocyte count, lactate dehydrogenase, β2-microglobulin, albumin, C-reactive protein, and ferritin—and the prognosis for survival in patients with multiple myeloma (MM) ..
|
|
|
Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients
Jae-Ho Yoon, Jong-Wook Kim, Young-Woo Jeon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park, Seok-Goo Cho
Korean J Intern Med. 2015;30(3):362-371. Published online April 29, 2015
Background/Aims: Several studies have demonstrated the effect of autologous hematopoietic stem cell transplantation (auto-HSCT) as a salvage treatment for patients with relapsed diffuse large B-cell lymphoma (DLBCL). However, the role of auto-HSCT as a frontline treatment has not been fully investig..
|
|
|
Is the Low-Thalidomide Dose MPT Regimen Beneficial?
Chang-Ki Min
Korean J Intern Med. 2011;26(4):400-402. Published online November 28, 2011
|
|
|
Bone Marrow T Cells are Superior to Splenic T Cells to Induce Chimeric Conversion After Non-Myeloablative Bone Marrow Transplantation
Hyun-Sil Park, Seok-Goo Cho, Min-Jung Park, So-Youn Min, Hong-Seok Chang, Hee-Je Kim, Seok Lee, Chang-Ki Min, Jong-Wook Lee, Woo-Sung Min, Chun-Choo Kim, Ho-Youn Kim
Korean J Intern Med. 2009;24(3):252-262. Published online August 26, 2009
Background/AimsThe bone marrow functions not only as the primary B-lymphocyte-producing organ but also as a secondary lymphoid organ for CD4 and CD8 cell responses and a site of preferential homing and persistence for memory T cells. Bone marrow T (BM-T) cells are distinguishe..
|
|
|
